Use of an inhibitor of CSF-1 activity for the treatment of inflammatory bowel disease

Details for Australian Patent Application No. 2004289098 (hide)

Owner UCB Pharma S.A.

Inventors Bourne, Timothy; Lawson, Alastair David Griffiths

Agent Watermark

Pub. Number AU-B-2004289098

PCT Pub. Number WO2005/046657

Priority 0325836.5 05.11.03 GB

Filing date 3 November 2004

Wipo publication date 26 May 2005

Acceptance publication date 1 July 2010

International Classifications

C07K 16/24 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 31/00 (2006.01)

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

Event Publications

25 May 2006 PCT application entered the National Phase

  PCT publication WO2005/046657 Priority application(s): WO2005/046657

14 February 2008 Assignment before Grant

  Celltech R&D Limited The application has been assigned to UCB Pharma S.A.

1 July 2010 Application Accepted

  Published as AU-B-2004289098

28 October 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004289102-Product and method for controlling flying insects

2004289092-Wound cleansing apparatus with scaffold